Phoma betae Allergy Shots: High Potency, Low Abundance, and the Alternaria Cross-Talk
Phoma betae is the sugar beet leaf spot pathogen with a striking allergenic paradox: despite being rarely aerosolized (pycnidial conidia in gelatinous masses, not dusty spores), SPT positivity reaches 36% in Canadian atopic cohorts with 83% of Phoma-positive patients also positive to Alternaria (Tarlo 1979). No SCIT RCT exists for Phoma — the positive result is a cross-reactivity marker pointing to the Alternaria SCIT pathway (Kuna 2011, Tabar 2019).
Phoma betae Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to phoma betae — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of phoma betae allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of phoma betae immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of phoma betae extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for phoma betae allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing phoma betae extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription phoma betae immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat phoma betae allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Phoma betae?
The biology, taxonomy, and clinical fingerprint of Phoma betae — the foundation of how SCIT targets it.
Phoma betae is a plant pathogen of sugar beet that despite rarely aerosolizing its gelatinous pycnidial conidia, reaches 36% SPT positivity in atopic populations — explained largely by its Alternaria cross-reactivity.
- Scientific name
- Phoma betae (modern taxonomy: Pleospora betae / Neocamarosporium betae)
- Family
- Pleosporaceae historically; Pleosporales (Dothideomycetes, Ascomycota)Pleosporales order
- Type
- Plant pathogen (sugar beet leaf spot) and indoor surface saprophyte on painted surfaces and window frames
- Native to
- Sugar beet growing regions worldwide; indoor environments including painted surfaces, concrete, rubber, window sealants
- Allergen proteins
- No WHO/IUIS-registered Phoma betae allergens individually designated as of 2024Pan-fungal cross-reactivity assumed via enolase, MnSOD, and serine protease (Crameri 2014)Strong Alternaria cross-reactivity — 83% of Phoma-sensitive patients also Alternaria-positive (Tarlo 1979)
- Particle size
- Unicellular hyaline conidia <15 µm exuded in gelatinous masses from pycnidia — NOT easily airborne
- Avoidance difficulty
- Moderate
How Phoma betae Allergy Presents
Symptoms by body system — useful for distinguishing Phoma betae sensitivity from overlapping allergies and infections.
Respiratory
- Allergic rhinitis during late-summer outdoor mold peak season — symptoms often indistinguishable from Alternaria rhinitis given 83% co-sensitization
- Asthma exacerbations in highly sensitized patients on high-outdoor-mold-count days
- Sugar beet field and processing facility occupational exposure in symptomatic farm workers
- Indoor rhinitis from window frame and painted surface colonization in humid environments
Ocular
- Allergic conjunctivitis during outdoor mold season — paralleling Alternaria season
- Eye irritation in sugar beet field workers during harvest
- Tearing and periorbital swelling in sensitized individuals
Dermal
- Atopic dermatitis flares correlating with outdoor Pleosporales spore peaks
- Non-specific pruritus during summer-fall mold season
- Rare subcutaneous phaeohyphomycosis in immunocompromised hosts — ~33 published cases, outside allergy scope (Revankar 2010)
Systemic
- Fatigue from chronic mold-season exposure
- Sleep disruption from uncontrolled rhinitis
- Reduced outdoor tolerance on high-spore late-summer afternoons
- Malaise correlating with peak mold-season exposure
Phoma betae is one of my favorite teaching examples of allergenic potency exceeding aeroallergen abundance. Pycnidial conidia in gelatinous masses should not produce 36% SPT positivity — yet Tarlo's 1979 data clearly shows they do, because 83% of those positives are really Alternaria cross-reactivity. When I see a Phoma positive, I reach for rAlt a 1 component testing to confirm the shared Pleosporales sensitization before designing the SCIT regimen.
When & Where Phoma betae Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Outdoor spore counts peak July-September paralleling Alternaria season; sugar beet processing exposure peaks at harvest time· Approximately 12-16 weeks of outdoor peak with concurrent Alternaria season; indoor exposure from painted surfaces and window frames is year-round
US Exposure Map
6 high-intensity statesWhat Phoma betae Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Phoma betae shows the strongest Alternaria cross-reactivity of any minor mold — 83% of Phoma-positive patients are also Alternaria-positive (Tarlo 1979), making Phoma sensitization primarily a confirmatory signal of Alternaria/Pleosporales primary sensitization.
83% of Phoma-positive patients also Alternaria-positive (Tarlo 1979); shared Pleosporales allergen repertoire via enolase and serine protease
Is SCIT Right for Your Phoma betae Allergy?
Answer five questions to assess whether your Phoma betae / Pleosporales sensitization warrants Alternaria-based SCIT evaluation.
How severe are your late-summer outdoor mold allergy symptoms?
The Phoma betae SCIT Protocol
Phoma betae sensitization is addressed via Alternaria-based SCIT — the operative evidence-anchored treatment for Pleosporales sensitization. Component testing (rAlt a 1, m6) confirms the shared primary sensitization before treatment initiation.
Weekly escalating Alternaria extract doses self-administered at home through Curex with a 30-minute self-observation period and a prescribed epinephrine auto-injector on hand; the first injection and every dose change are Zoom-supervised by the care team. Mold vials separated from pollen extracts. Pre-injection peak flow check recommended given Pleosporales-asthma severity link.
Monthly or every-2-4-week maintenance injections. rAlt a 1 component monitoring and symptom tracking guide dose decisions.
Discontinuation evaluation per standard Alternaria SCIT protocol after 3-5 years.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Phoma betae SCIT
No SCIT RCT exists for Phoma betae. Given 83% Alternaria co-sensitization, the Alternaria DBPC-RCT data provides the operative evidence framework for SCIT decisions in Phoma-positive patients.
- Alternaria SCIT: Combined symptom-medication score reduction (primary evidence for Phoma cross-reactive sensitization)63%Kuna et al., J Allergy Clin Immunol 2011, N=111 children, DBPC-RCT
- Alternaria SCIT: Efficacy after 1 year with native Alt a 140%Tabar et al., J Allergy Clin Immunol 2019, DBPC-RCT
No Phoma betae-specific SCIT RCT exists. The 83% co-sensitization rate with Alternaria (Tarlo 1979) makes Alternaria DBPC-RCT data (Kuna 2011: 63.5% combined score reduction; Tabar 2019: significant 1-year improvement) the most directly applicable evidence framework for Phoma-positive patients who also have confirmed Alternaria primary sensitization.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Phoma betae SCIT Side Effects
Side effects of Alternaria-based mold SCIT apply when Phoma betae sensitization is managed via the Alternaria pathway.
Local reactions
4 documentedSystemic reactions
4 documentedAll mold SCIT requires epinephrine and a mandatory 30-minute post-injection observation period — with Curex, you self-observe at home with a prescribed epinephrine auto-injector, and the first injection and every dose change are Zoom-supervised by the care team. Asthmatic patients require pre-injection peak flow measurement.
SCIT vs Alternatives for Phoma betae
Phoma betae sensitization management follows the same pathway as Alternaria sensitization given 83% co-occurrence.
| Criterion | SCIT (Alternaria-based)Best | SLIT drops | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | 63% combined score reduction (Kuna 2011) for confirmed Pleosporales | Alternaria SLIT shows improvement (Cortellini 2010) | Partial — outdoor Pleosporales avoidance is limited | Symptomatic control only |
| 5-yr cost | $3,500-$8,000 over 5 years | $500-$2,000/yr | HEPA $100-$500/yr | $500-$2,000/yr ongoing |
| Duration | 3-5 years | 3-5 years | Ongoing | Ongoing |
| Convenience | Weekly then monthly clinic visits | Daily at-home | Lifestyle modifications | Daily pills/sprays |
| Safety | Systemic reactions <1%; 30-min obs | Lower systemic risk | No injection risks | Drug side effects |
| Lasting effect | Yes — tolerance may persist | Less robust evidence for molds | No lasting desensitization effect | No lasting effect |
SCIT (Alternaria-based)Best
SLIT drops
Avoidance
Medications
For confirmed Phoma/Alternaria Pleosporales sensitization, Alternaria-based SCIT is the best-evidenced immunotherapy. Curex pairs Phoma betae (m13) with Alternaria (m6) and rAlt a 1 component testing to clarify whether the positive reflects shared Pleosporales sensitization. Curex then delivers that disease-modifying SCIT as weekly at-home self-injections at $129/month, with allergist oversight via telehealth, a prescribed epinephrine auto-injector confirmed on hand, and Zoom-supervised dosing for the first injection and every dose change — discuss candidacy with your allergist.
What Phoma betae SCIT Actually Costs
Most major insurers cover mold SCIT under standard allergy benefits when ordered by a board-certified allergist. Phoma betae-specific SCIT is managed as Alternaria-based mold SCIT for billing purposes.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your phoma betae allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Phoma betae SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
This is the central paradox of Phoma betae allergy. Phoma pycnidial conidia are extruded in gelatinous masses from their spore-producing structures (pycnidia) rather than released as dry dusty spores, making them far less readily airborne than Alternaria or Cladosporium. Yet Tarlo's 1979 Canadian study found 36% SPT positivity in atopic subjects — comparable to some much more abundant molds. The explanation lies in cross-reactivity: 83% of those Phoma-positive patients were also Alternaria-positive, and their Phoma IgE largely reflects shared Pleosporales allergen repertoire (enolase, MnSOD, serine proteases) rather than primary Phoma sensitization from direct Phoma spore inhalation. Phoma's apparent 'potency' is partly borrowed from its Alternaria cross-reactivity rather than genuine high-dose exposure.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.